ADCT
ADC Therapeutics S.A.
There isn't enough reported data to score ADCT yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ADCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ADCT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ADCT PE Valuation
ADCT has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ADCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ADCT's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ADCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.53 | +$0.89 |
| Q2 2026 | -$0.67 | +$0.87 |
| Q1 2026 | -$1.06 | +$0.36 |
| Q4 2025 | -$1.21 | +$0.41 |
| Q3 2025 | -$1.42 | +$0.97 |
| Q2 2025 | -$1.54 | +$1.01 |
| Q1 2025 | -$1.42 | +$1.33 |
| Q4 2024 | -$1.62 | +$1.30 |
ADCT is still losing money, but far less than before: $0.53 per share over the past year, against $3.71 at its worst in late 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ADCT on earnings quality, reporting a profit while its opponent remains loss making.
ADCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $21.7M | +32% |
| Q2 2026 | $19.2M | +2.2% |
| Q1 2026 | $20.9M | -9.5% |
| Q4 2025 | $23.1M | +36% |
| Q3 2025 | $16.4M | -11% |
| Q2 2025 | $18.8M | +8.2% |
| Q1 2025 | $23M | +28% |
| Q4 2024 | $16.9M | +0.7% |
ADCT's revenue is recovering but still below its 2022 peak: $22M last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -66% | +122 points |
| Q2 2026 | -132% | +102 points |
| Q1 2026 | -121% | +2.5 points |
| Q4 2025 | -78% | +114 points |
| Q3 2025 | -189% | +4.1 points |
| Q2 2025 | -234% | -68 points |
| Q1 2025 | -124% | +63 points |
| Q4 2024 | -192% | +46 points |
ADCT's operating margin was −66% last quarter, up 122 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ADCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ADCT on profitability, with a higher operating margin.
ADCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.9M | +$1.8M |
| Q2 2026 | -$11.8M | +$12.3M |
| Q1 2026 | -$29.7M | +$26.9M |
| Q4 2025 | -$31.1M | -$9.2M |
| Q3 2025 | -$29.6M | -$4.4M |
| Q2 2025 | -$24.1M | +$8.8M |
| Q1 2025 | -$56.6M | -$12M |
| Q4 2024 | -$21.9M | +$11.1M |
ADCT has burned cash in almost every quarter: −$101M over the past year, against −$132M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ADCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ADCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +394K shares |
| 1 year | +14% | +19M shares |
| 3 years | +89% | +73.2M shares |
| 5 years | +103% | +78.7M shares |
| Available history | +112% | +82.2M shares |
ADCT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $218,871 |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ADCT Net Leverage
ADCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ADCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 61.0 | Neutral |
ADCT's weekly RSI is 44 (neutral) and its Stochastic is 61 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ADCT PE vs Healthcare Sector
ADCT has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ADCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.44 | 2.1% below |
| 20 week MA | $1.26 | 12% above |
| 50 week MA | $2.55 | 45% below |
| 100 week MA | $2.60 | 46% below |
| 200 week MA | $2.64 | 47% below |
ADCT's trend is mixed: it's above one of its five weekly moving averages, and 47% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ADCT on trend strength, trading above more of its moving averages.
ADCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.7 | $37.0 | +25% |
| 2021 | $37.0 | $21.3 | -43% |
| 2022 | $21.3 | $3.52 | -83% |
| 2023 | $3.52 | $1.66 | -53% |
| 2024 | $1.66 | $2.03 | +22% |
| 2025 | $2.03 | $3.51 | +73% |
| 2026 YTD | $3.51 | $1.41 | -60% |
ADCT has finished lower in three of the last six years. It's down 60% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ADCT on returns for 2026, with the stronger performance.